Cargando…
Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function
BACKGROUND: Late infantile neuronal ceroid lipofuscinosis (LINCL), one form of Batten’s disease is a progressive neurodegenerative disorder resulting from a CLN2 gene mutation. The spectrum of ophthalmic manifestations of LINCL and the relationship with neurological function has not been previously...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756041/ https://www.ncbi.nlm.nih.gov/pubmed/24015292 http://dx.doi.org/10.1371/journal.pone.0073128 |
_version_ | 1782282027134877696 |
---|---|
author | Orlin, Anton Sondhi, Dolan Witmer, Matthew T. Wessel, Matthew M. Mezey, Jason G. Kaminsky, Stephen M. Hackett, Neil R. Yohay, Kaleb Kosofsky, Barry Souweidane, Mark M. Kaplitt, Michael G. D’Amico, Donald J. Crystal, Ronald G. Kiss, Szilárd |
author_facet | Orlin, Anton Sondhi, Dolan Witmer, Matthew T. Wessel, Matthew M. Mezey, Jason G. Kaminsky, Stephen M. Hackett, Neil R. Yohay, Kaleb Kosofsky, Barry Souweidane, Mark M. Kaplitt, Michael G. D’Amico, Donald J. Crystal, Ronald G. Kiss, Szilárd |
author_sort | Orlin, Anton |
collection | PubMed |
description | BACKGROUND: Late infantile neuronal ceroid lipofuscinosis (LINCL), one form of Batten’s disease is a progressive neurodegenerative disorder resulting from a CLN2 gene mutation. The spectrum of ophthalmic manifestations of LINCL and the relationship with neurological function has not been previously described. METHODS: Patients underwent ophthalmic evaluations, including anterior segment and dilated exams, optical coherence tomography, fluorescein and indocyanine green angiography. Patients were also assessed with the LINCL Neurological Severity Scale. Ophthalmic findings were categorized into one of five severity scores, and the association of the extent of ocular disease with neurological function was assessed. RESULTS: Fifty eyes of 25 patients were included. The mean age at the time of exam was 4.9 years (range 2.5 to 8.1). The mean ophthalmic severity score was 2.6 (range 1 to 5). The mean neurological severity score was 6.1 (range 2 to 11). Significantly more severe ophthalmic manifestations were observed among older patients (p<0.005) and patients with more severe neurological findings (p<0.03). A direct correlation was found between the Ophthalmic Severity Scale and the Weill Cornell Neurological Scale (p<0.002). A direct association was also found between age and the ophthalmic manifestations (p<0.0002), with older children having more severe ophthalmic manifestations. CONCLUSIONS: Ophthalmic manifestations of LINCL correlate closely with the degree of neurological function and the age of the patient. The newly established LINCL Ophthalmic Scale may serve as an objective marker of LINCL severity and disease progression, and may be valuable in the evaluation of novel therapeutic strategies for LINCL, including gene therapy. |
format | Online Article Text |
id | pubmed-3756041 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37560412013-09-06 Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function Orlin, Anton Sondhi, Dolan Witmer, Matthew T. Wessel, Matthew M. Mezey, Jason G. Kaminsky, Stephen M. Hackett, Neil R. Yohay, Kaleb Kosofsky, Barry Souweidane, Mark M. Kaplitt, Michael G. D’Amico, Donald J. Crystal, Ronald G. Kiss, Szilárd PLoS One Research Article BACKGROUND: Late infantile neuronal ceroid lipofuscinosis (LINCL), one form of Batten’s disease is a progressive neurodegenerative disorder resulting from a CLN2 gene mutation. The spectrum of ophthalmic manifestations of LINCL and the relationship with neurological function has not been previously described. METHODS: Patients underwent ophthalmic evaluations, including anterior segment and dilated exams, optical coherence tomography, fluorescein and indocyanine green angiography. Patients were also assessed with the LINCL Neurological Severity Scale. Ophthalmic findings were categorized into one of five severity scores, and the association of the extent of ocular disease with neurological function was assessed. RESULTS: Fifty eyes of 25 patients were included. The mean age at the time of exam was 4.9 years (range 2.5 to 8.1). The mean ophthalmic severity score was 2.6 (range 1 to 5). The mean neurological severity score was 6.1 (range 2 to 11). Significantly more severe ophthalmic manifestations were observed among older patients (p<0.005) and patients with more severe neurological findings (p<0.03). A direct correlation was found between the Ophthalmic Severity Scale and the Weill Cornell Neurological Scale (p<0.002). A direct association was also found between age and the ophthalmic manifestations (p<0.0002), with older children having more severe ophthalmic manifestations. CONCLUSIONS: Ophthalmic manifestations of LINCL correlate closely with the degree of neurological function and the age of the patient. The newly established LINCL Ophthalmic Scale may serve as an objective marker of LINCL severity and disease progression, and may be valuable in the evaluation of novel therapeutic strategies for LINCL, including gene therapy. Public Library of Science 2013-08-28 /pmc/articles/PMC3756041/ /pubmed/24015292 http://dx.doi.org/10.1371/journal.pone.0073128 Text en © 2013 Orlin et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Orlin, Anton Sondhi, Dolan Witmer, Matthew T. Wessel, Matthew M. Mezey, Jason G. Kaminsky, Stephen M. Hackett, Neil R. Yohay, Kaleb Kosofsky, Barry Souweidane, Mark M. Kaplitt, Michael G. D’Amico, Donald J. Crystal, Ronald G. Kiss, Szilárd Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function |
title | Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function |
title_full | Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function |
title_fullStr | Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function |
title_full_unstemmed | Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function |
title_short | Spectrum of Ocular Manifestations in CLN2-Associated Batten (Jansky-Bielschowsky) Disease Correlate with Advancing Age and Deteriorating Neurological Function |
title_sort | spectrum of ocular manifestations in cln2-associated batten (jansky-bielschowsky) disease correlate with advancing age and deteriorating neurological function |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756041/ https://www.ncbi.nlm.nih.gov/pubmed/24015292 http://dx.doi.org/10.1371/journal.pone.0073128 |
work_keys_str_mv | AT orlinanton spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT sondhidolan spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT witmermatthewt spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT wesselmatthewm spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT mezeyjasong spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT kaminskystephenm spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT hackettneilr spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT yohaykaleb spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT kosofskybarry spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT souweidanemarkm spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT kaplittmichaelg spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT damicodonaldj spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT crystalronaldg spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction AT kissszilard spectrumofocularmanifestationsincln2associatedbattenjanskybielschowskydiseasecorrelatewithadvancingageanddeterioratingneurologicalfunction |